Treatment decisions for breast cancer largely depend on clinicopathological parameters (tumor size, hormone receptor status, HER2 status, Ki-67 index, pathological grade, lymph node metastasis and distant metastasis). The gene discussed is ERBB2; the disease is neoplasm.